Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1] Group 1: Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [1] - Only 57.3% of patients in the trial were on the highest dosage of CagriSema, as participants were allowed to modify their own dosage during the trial [1] Group 2: Stock Price Impact - Following the announcement of the trial results, Novo's stock price decreased by $18.44 per share, closing at $85.00 per share [1] Group 3: Class Action Information - Shareholders who purchased shares of NVO during the class period from November 2, 2022, to December 19, 2024, are encouraged to register for a class action lawsuit [2] - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [2]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. - There is no cost or obligation for shareholders to participate in this class action [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].